Rivaroxaban News and Research

RSS

Rivaroxaban reduces the occurrence of severe ischemic events in patients with peripheral artery disease

Rivaroxaban, in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients with symptomatic peripheral artery disease (PAD) who underwent lower extremity revascularization, a procedure to open blocked arteries in the leg.

17 May 2021

Study shows adverse outcomes associated with use of more blood thinners

More blood thinners aren't automatically better, another study confirms. A new publication in JAMA Internal Medicine focuses on the minimal pros and the concerning cons of combining a daily aspirin with a drug from the newer class of anticoagulants that include apixaban, dabigatran, edoxaban and rivaroxaban.

19 Apr 2021

Dual-pathway approach can lead to better outcomes in patients with heart stents

Pairing a blood-thinning drug with aspirin daily for patients who have an angioplasty with a stent can contribute to better health outcomes, including lower risk of death, than aspirin alone, according to a recent study by cardiologists at the University of Alberta and Mazankowski Alberta Heart Institute.

28 May 2020

Study provides indications and techniques of lower extremity revascularization

Lower extremity artery disease is a leading cause of morbidity and mortality worldwide, affecting hundreds of millions of people.

7 May 2020

Clopidogrel added to aspirin and rvaroxaban shows no additional benefit for peripheral artery disease

The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing lower extremity revascularization--a procedure to treat blocked arteries in the leg--had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.

31 Mar 2020

Direct oral anticoagulant more effective in lowering risk of VTE after common orthopedic surgeries

The direct oral anticoagulant rivaroxaban dramatically cut the likelihood of serious venous thromboembolism (VTE) in people recovering from lower limb orthopedic surgery requiring immobilization in comparison with enoxaparin, another anticoagulant agent, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Oral apixaban as effective as dalteparin for treating blood clots in people with cancer

For people with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low molecular weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), or blood clot, with no excess in major bleeding events, according to Phase 3 trial results presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Low-dose rivaroxaban reduces adverse heart events in symptomatic PAD post-intervention

People with symptomatic peripheral artery disease who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg (lower extremity revascularization) had a 15% reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

New research provides welcomed news for countless patients taking PPIs

For patients taking proton pump inhibitors to treat gastroesophageal disease (GERD) or other acid-related conditions, new research puts safety concerns to rest.

7 Jun 2019

Using blood thinners in heart failure patients associated with reduced risk of thromboembolic events

Researchers at University of California San Diego School of Medicine found that using blood thinners in patients with worsening heart failure, coronary artery disease or irregular heart rhythms was associated with a 17 percent reduced risk of thromboembolic events, such as stroke and heart attack.

25 Apr 2019

Drug that reverses blood thinning effects stops acute life-threatening bleeding

A drug that reverses the blood thinning effects of factor Xa inhibitors effectively stopped acute life-threatening bleeding in patients taking a factor Xa inhibitor blood thinner drug, according to late breaking science presented at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.

8 Feb 2019

Proton pump inhibitors in combination with oral anticoagulants reduce GI bleeding risk

A Vanderbilt University Medical Centerstudy published today in JAMA shows that patients already at higher risk for gastrointestinal bleeding gain a marked protection from this risk when they take a proton pump inhibitor in combination with an oral anticoagulant.

4 Dec 2018

Aspirin may be effective in preventing blood clots after knee replacement

When it comes to preventing blood clots after a knee replacement, good old aspirin may be just as effective as newer, more expensive drugs.

22 Oct 2018

Incidence of stroke has risen steadily among marijuana users, show studies

11th World Stroke Congress brings together leading international stroke experts and an unparalleled scientific program covering epidemiology, prevention, acute care, rehabilitation and recovery in 100s of sessions and oral posters.

19 Oct 2018

Anticoagulant use in East Asian patients with nonvalvular atrial fibrillation

In the current issue of Cardiovascular Innovations and Applications (Volume3,Number 2, 2018, pp. 215-226(12); DOI: https://doi.org/10.15212/CVIA.2017.0033 Chang-Sheng Ma from the Department of Cardiology, Beijing AnZhen Hospital, Capital Medical University, Beijing, China considers the use of direct oral anticoagulants for prevention of stroke and systemic embolic events in East Asian patients with nonvalvular atrial fibrillation.

11 Sep 2018

Major bleeding associated with subsequent cancer diagnoses

Bleeding in patients treated with anticoagulants should stimulate a search for cancer, according to late breaking results from the COMPASS trial presented today at ESC Congress 2018.

28 Aug 2018

Antithrombin drug does not reduce risk of myocardial infarction, stroke in heart failure patients

The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction and stroke after an episode of worsening heart failure in patients with heart failure, sinus rhythm, and coronary artery disease, according to late breaking results from the COMMANDER HF trial presented today in a Hot Line Session at ESC Congress 2018 and with simultaneous publication in NEJM.

27 Aug 2018

Cardiovascular disease patients with internal bleeding more likely to be diagnosed with cancer

Patients with cardiovascular disease who develop major internal bleeding are much more likely to be diagnosed with cancer, a large international clinical trial has found.

27 Aug 2018

Oral anticoagulant use after hospital discharge may offer protection from non-fatal blood clots

The use of an oral anticoagulant medicine in medically ill patients for 45 days following their discharge from the hospital reduces the rate of non-fatal symptomatic blood clots with no impact on fatal blood clots, according to late breaking results from the MARINER trial presented today in a Hot Line Session at ESC Congress 2018 and published in The New England Journal of Medicine.

27 Aug 2018

Direct oral anticoagulants associated with reduced risks of major bleeding

New drugs known as direct oral anticoagulants used to treat serious blood clots are associated with reduced risks of major bleeding compared with the older anti-clotting drug, warfarin, finds a study in The BMJ today.

5 Jul 2018

Rivaroxaban News and Research

Rivaroxaban reduces the occurrence of severe ischemic events in patients with peripheral artery disease

Study shows adverse outcomes associated with use of more blood thinners

Dual-pathway approach can lead to better outcomes in patients with heart stents

Study provides indications and techniques of lower extremity revascularization

Clopidogrel added to aspirin and rvaroxaban shows no additional benefit for peripheral artery disease

Direct oral anticoagulant more effective in lowering risk of VTE after common orthopedic surgeries

Oral apixaban as effective as dalteparin for treating blood clots in people with cancer

Low-dose rivaroxaban reduces adverse heart events in symptomatic PAD post-intervention

New research provides welcomed news for countless patients taking PPIs

Using blood thinners in heart failure patients associated with reduced risk of thromboembolic events

Drug that reverses blood thinning effects stops acute life-threatening bleeding

Proton pump inhibitors in combination with oral anticoagulants reduce GI bleeding risk

Aspirin may be effective in preventing blood clots after knee replacement

Incidence of stroke has risen steadily among marijuana users, show studies

Anticoagulant use in East Asian patients with nonvalvular atrial fibrillation

Major bleeding associated with subsequent cancer diagnoses

Antithrombin drug does not reduce risk of myocardial infarction, stroke in heart failure patients

Cardiovascular disease patients with internal bleeding more likely to be diagnosed with cancer

Oral anticoagulant use after hospital discharge may offer protection from non-fatal blood clots

Direct oral anticoagulants associated with reduced risks of major bleeding

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News